Cover Image
市場調查報告書

克隆氏症治療藥市場及開發平台分析

Crohn's Disease Drug Market and Pipeline Analysis

出版商 PNS Pharma 商品編碼 308692
出版日期 內容資訊 英文 297 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
克隆氏症治療藥市場及開發平台分析 Crohn's Disease Drug Market and Pipeline Analysis
出版日期: 2014年05月01日 內容資訊: 英文 297 Pages
簡介

本報告提供克隆氏症治療藥市場相關調查,彙整市場概要,Phase、國別臨床實驗分析,上市藥,臨床實驗暫停、中止的藥物簡介及競爭情形等資料,為您概述為以下內容。

第1章 克隆氏症市場概要

  • 市場概要
  • 臨床實驗平台分析

第2章 克隆氏症治療藥的開發相關EMA指南

第3章 克隆氏症臨床實驗分析:Phase、國別

  • 未確認階段
  • 研究
  • 前臨床
  • 臨床
  • 階段I
  • 階段I/II
  • 階段II
  • 階段II/III
  • 階段III
  • 預註冊

第3章 已上市克隆氏症治療藥:臨床簡介·專利分析

  • Adalimumab( Humira)
  • Budesonide Capsules (Entocort)
  • Certolizumab Pegol (Cimzia)
  • Infliximab (Remicade)
  • Infliximab Biosimilar (Inflectra)
  • Mesalazine Controlled Release(Pentasa)
  • Natalizumab (Tysabri)
  • TJ 114
  • Vapreotide (Docrised)

第4章 暫停、中止的治療藥簡介:臨床Phase、國別

  • 未開發
  • 中止
  • 停止

第5章 競爭情形

  • Amgen
  • Boehringer Ingelheim
  • Cambridge Antibody Technology (MedImmune)
  • Centocor (Janssen Biotech)
  • Pfizer
  • Tillotts Pharma (Zeria Pharmaceutical)

圖表清單

目錄

Under the umbrella of inflammatory bowel diseases, Crohn's disease and ulcerative colitis are two most common disorders. Though both these disorders have similar symptoms, the difference arises in the areas affected in the gastrointestinal tract (GI tract). The Crohn's disease in most cases affects the end of the small bowel (the ileum) and the beginning of the colon, but it may affect any part of the gastrointestinal (GI) tract, from the mouth to the anus. On the other hand, ulcerative colitis affects only the colon, which is also called the large intestine. Additionally, there is also the possibility of Crohn's disease affecting the entire thickness of the bowel wall, while ulcerative colitis only impacts the innermost lining of the colon. Also, in Crohn's disease, the inflammation of the intestine can miss some normal areas in between patches of diseased intestine, which does not occur in ulcerative colitis. It has been observed that though age is no basis for this disease, Crohn's is more prevalent among adolescents and young adults between the ages of 15 and 35.

Pharmaceutical companies have been increasingly attracted towards developing many new drug compounds for Crohn's disease owing to the size of the market and the limitations of current treatments. There is a variety of therapies, both current and future, which are based on different mechanisms of action including TNF-alpha inhibitors, IL-12 and 23 inhibitors, IL-6 inhibitors, IL-17 inhibitors, chemokine receptor inhibitors, co-stimulation modulators, anti-CD3 molecules, anti-MAP agents, cell adhesion molecule inhibitors, oral adsorbents, other immunosupressants, and stem cell therapy.

There is significant room for future discovery in the market for Crohn's disease drugs. As the exact causes are still unknown, the appropriate cure is yet to be developed. However, there are new studies which are under way, and the medications which have been recently introduced in the market are proving to be efficient to a certain extent. It is expected that the future of Crohn's disease market would witness significant improvements in the diagnostic techniques as the researchers would get a deeper understanding of the disease. Thus, overall, there is significant amount of research currently underway for developing newer and innovative drug compounds to treat patients with Crohn's disease. With the launch of the new compounds in the next 3-5 years, it is most likely that this market would offer better solutions for the patients.

“Crohn's Disease Drug Market and Pipeline Analysis” Report Highlight:

  • Crohn's Disease Market Overview
  • Crohn's Disease Clinical Trial Insight by Phase & Country
  • Competitive Landscape
  • Crohn's Disease Drug Clinical Development Phase: 79
  • Majority Drugs in Phase-II Development: 30
  • Marketed Drugs: 9
  • Suspended & Discontinued Drugs: 86

Table of Contents

1. Crohn's Disease Market Overview

  • 1.1. Market Overview
  • 1.2. Clinical Pipeline Insight

2. EMA Guidelines on Development Crohn's Disease Drug

3. Crohn's Disease Clinical Trial Insight by Phase & Country

  • 3.1. Unknown Phase
  • 3.2. Research
  • 3.3. Preclinical
  • 3.4. Clinical
  • 3.5. Phase-I
  • 3.6. Phase-I/II
  • 3.7. Phase-II
  • 3.8. Phase-II/III
  • 3.9. Phase-III
  • 3.10. Preregistration

4. Marketed Crohn's Disease Drugs: Clinical Profile & Patent Insight

  • 4.1. Adalimumab( Humira)
  • 4.2. Budesonide Capsules (Entocort)
  • 4.3. Certolizumab Pegol (Cimzia)
  • 4.4. Infliximab (Remicade)
  • 4.5. Infliximab Biosimilar (Inflectra)
  • 4.6. Mesalazine Controlled Release(Pentasa)
  • 4.7. Natalizumab (Tysabri)
  • 4.8. TJ 114
  • 4.9. Vapreotide (Docrised)

5. Suspended & Discontinued Profiles by Clinical Phase & County

  • 5.1. No Development Reported
  • 5.2. Discontinued
  • 5.3. Suspended

6. Competitive Landscape

  • 6.1. Amgen
  • 6.2. Boehringer Ingelheim
  • 6.3. Cambridge Antibody Technology (MedImmune)
  • 6.4. Centocor (Janssen Biotech)
  • 6.5. Pfizer
  • 6.6. Tillotts Pharma (Zeria Pharmaceutical)

List of Figures

  • Figure 1-1: Crohn's Disease Drug Clinical Pipeline by Phase (%), 2014
  • Figure 1-2: Number of Crohn's Disease Drug Clinical Pipeline by Phase, 2014
  • Figure 1-3: No Development in Crohn's Disease Drug by Phase (%), 2014
  • Figure 1-4: No Development in Crohn's Disease Drug by Phase (Number), 2014
  • Figure 1-5: Discontinued Crohn's Disease Drug by Phase (%), 2014
  • Figure 1-6: Number of Discontinued Crohn's Disease Drug by Phase, 2014
  • Figure 1-7: Suspended Crohn's Disease Drug by Phase (%), 2014
  • Figure 1-8: Number of Suspended Crohn's Disease Drug by Phase, 2014
Back to Top